Study on Allopregnanolone and Depression in Perimenopausal Women

Phase 4 Terminated 2 enrolled Brigham and Women's Hospital

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.

Timeline

Start: 2022-11-04
Primary completion: 2023-07-18
Completion: 2023-07-18

Outcome

Outcome not reported

Stopped (Enrollment): “low enrollment”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brexanolone	Unknown	—	Intravenous

Study on Allopregnanolone and Depression in Perimenopausal Women

Summary

Timeline

Outcome

Drugs

Indications